Overview

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Status:
Completed
Trial end date:
2016-04-04
Target enrollment:
Participant gender:
Summary
This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Celgene Corporation
Treatments:
Apremilast
Etanercept
Thalidomide